EGFR and glioma: Previous studies have shown that IDH-mut glioma patients had a better prognosis than those with wild-type IDH, across all WHO grades (11, 40), that EGFR amplification was correlated with poor prognosis (59), and that PTEN mutations could promote the infiltration of immunosuppressive tumor-associated macrophages (TAMs) (60).